Skip to main content

Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.

Publication ,  Journal Article
Easterhoff, D; Moody, MA; Fera, D; Cheng, H; Ackerman, M; Wiehe, K; Saunders, KO; Pollara, J; Vandergrift, N; Parks, R; Kim, J; Michael, NL ...
Published in: PLoS Pathog
February 2017

UNLABELLED: The canary pox vector and gp120 vaccine (ALVAC-HIV and AIDSVAX B/E gp120) in the RV144 HIV-1 vaccine trial conferred an estimated 31% vaccine efficacy. Although the vaccine Env AE.A244 gp120 is antigenic for the unmutated common ancestor of V1V2 broadly neutralizing antibody (bnAbs), no plasma bnAb activity was induced. The RV305 (NCT01435135) HIV-1 clinical trial was a placebo-controlled randomized double-blinded study that assessed the safety and efficacy of vaccine boosting on B cell repertoires. HIV-1-uninfected RV144 vaccine recipients were reimmunized 6-8 years later with AIDSVAX B/E gp120 alone, ALVAC-HIV alone, or a combination of ALVAC-HIV and AIDSVAX B/E gp120 in the RV305 trial. Env-specific post-RV144 and RV305 boost memory B cell VH mutation frequencies increased from 2.9% post-RV144 to 6.7% post-RV305. The vaccine was well tolerated with no adverse events reports. While post-boost plasma did not have bnAb activity, the vaccine boosts expanded a pool of envelope CD4 binding site (bs)-reactive memory B cells with long third heavy chain complementarity determining regions (HCDR3) whose germline precursors and affinity matured B cell clonal lineage members neutralized the HIV-1 CRF01 AE tier 2 (difficult to neutralize) primary isolate, CNE8. Electron microscopy of two of these antibodies bound with near-native gp140 trimers showed that they recognized an open conformation of the Env trimer. Although late boosting of RV144 vaccinees expanded a novel pool of neutralizing B cell clonal lineages, we hypothesize that boosts with stably closed trimers would be necessary to elicit antibodies with greater breadth of tier 2 HIV-1 strains. TRIAL REGISTRATION: ClinicalTrials.gov NCT01435135.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

PLoS Pathog

DOI

EISSN

1553-7374

Publication Date

February 2017

Volume

13

Issue

2

Start / End Page

e1006182

Location

United States

Related Subject Headings

  • Virology
  • Surface Plasmon Resonance
  • Polymerase Chain Reaction
  • Neutralization Tests
  • Microscopy, Electron
  • Immunization, Secondary
  • Image Processing, Computer-Assisted
  • Humans
  • HIV-1
  • HIV Infections
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Easterhoff, D., Moody, M. A., Fera, D., Cheng, H., Ackerman, M., Wiehe, K., … Haynes, B. F. (2017). Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. PLoS Pathog, 13(2), e1006182. https://doi.org/10.1371/journal.ppat.1006182
Easterhoff, David, M Anthony Moody, Daniela Fera, Hao Cheng, Margaret Ackerman, Kevin Wiehe, Kevin O. Saunders, et al. “Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.PLoS Pathog 13, no. 2 (February 2017): e1006182. https://doi.org/10.1371/journal.ppat.1006182.
Easterhoff, David, et al. “Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.PLoS Pathog, vol. 13, no. 2, Feb. 2017, p. e1006182. Pubmed, doi:10.1371/journal.ppat.1006182.
Easterhoff D, Moody MA, Fera D, Cheng H, Ackerman M, Wiehe K, Saunders KO, Pollara J, Vandergrift N, Parks R, Kim J, Michael NL, O’Connell RJ, Excler J-L, Robb ML, Vasan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Nitayaphan S, Sinangil F, Tartaglia J, Phogat S, Kepler TB, Alam SM, Liao H-X, Ferrari G, Seaman MS, Montefiori DC, Tomaras GD, Harrison SC, Haynes BF. Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. PLoS Pathog. 2017 Feb;13(2):e1006182.

Published In

PLoS Pathog

DOI

EISSN

1553-7374

Publication Date

February 2017

Volume

13

Issue

2

Start / End Page

e1006182

Location

United States

Related Subject Headings

  • Virology
  • Surface Plasmon Resonance
  • Polymerase Chain Reaction
  • Neutralization Tests
  • Microscopy, Electron
  • Immunization, Secondary
  • Image Processing, Computer-Assisted
  • Humans
  • HIV-1
  • HIV Infections